,

All PolarisDMD sites are now launched

Catabasis announces that all 40 sites, across eight countries, are now fully launched for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy!

La Force is happy to share the latest edition of the Catabasis Connection newsletter about the Phase 3 PolarisDMD trial for edasalonexent in Duchenne. The Phase 3 PolarisDMD trial is enrolling boys affected by Duchenne ages 4 to 7, any mutation type, that are not on steroids. This newsletter includes an illustration of the PolarisDMD and GalaxyDMD patient experience.

Clinical trial sites are enrolling rapidly. There is limited space in the United States, Canada and Australia. Locations in the UK, Germany, Ireland, Sweden, and Israel are at capacity. Catabasis anticipates that the final patient screening visits will be completed this September. If you have any questions about the trial > DMDtrials@catabasis.com

Link to the PDF file > https://www.catabasis.com/Catabasis%20Connection%20No.20.pdf

About edasalonexent

Edasalonexent inhibits NF-kB, a protein that plays a fundamental role in skeletal and cardiac muscle disease in Duchenne. By inhibiting NF-kB, edasalonexent has the potential to decrease inflammation and fibrosis, promote muscle regeneration, and slow disease progression. Edasalonexent is being developed as a potential stand-alone therapy and also have the potential to be combined with dystrophin-targeted therapies.

Learn more about edasalonexent

  • Watch this video recorded in November 2016, Dr. Joanne Donovan answers our questions about edasalonexent (CAT-1004)

About Canadian sitesClinical trials in Canada –  PHASE 3 POLARISDMD TRIAL OF EDASALONEXENT IS NOW OPEN FOR ENROLLMENT IN CANADA

About Catabasis

Their mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Their global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and the Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.

Stay in touch with Catabasis

Edasalonexent is an investigational drug that is not yet approved in any territory.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.